Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
| Autor: | Karim Fizazi, Clément Dumont, Pernelle Lavaud, Ronan Flippot, Giulia Baciarello, Constance Thibault, Yohann Loriot, Alina Fuerea, Laurence Albiges, Emeline Colomba |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Review Castration resistant urologic and male genital diseases lcsh:RC254-282 castration resistance Androgen deprivation therapy 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Castration Resistance Internal medicine medicine Enzalutamide 030212 general & internal medicine apalutamide enzalutamide business.industry darolutamide Apalutamide non-metastatic setting lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease prostate cancer Androgen receptor Darolutamide chemistry 030220 oncology & carcinogenesis business next generation androgen receptor inhibitors |
| Zdroj: | Therapeutic Advances in Medical Oncology Therapeutic Advances in Medical Oncology, Vol 12 (2020) |
| ISSN: | 1758-8340 |
| Popis: | Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|